Quantitative review of antibody response to inactivated seasonal influenza vaccines
Open Access
- 13 June 2011
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 6 (1) , 52-62
Abstract
Please cite this paper as: Seidman et al. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6(1), 52–62.Background Seasonal influenza epidemics are associated with significant morbidity and mortality each year, particularly amongst young children and the elderly. Seasonal influenza vaccines have been available for decades, yet influenza remains a major public health threat in the US, sparking interest in studies evaluating the effectiveness of vaccination.Objectives We sought to identify determinants of serological responses to inactivated seasonal influenza vaccines including number of doses, adjuvant, and subject characteristics.Methods We reviewed 60 articles published between 1987 and 2006. We used weighted multiple logistic regression and random‐effects models to evaluate how seroconversion and seroprotection rates varied with host and vaccine factors.Results Both children and seniors tended to have poorer immune responses compared to adults whereas use of adjuvant and a second vaccine dose tended to improve immune response. Pre‐vaccination serological status had a large impact on the immune response to vaccination. We found substantial heterogeneity among studies, even with similar population settings and vaccination regimen.Conclusions Future studies should stratify their results by pre‐vaccination serological status in an effort to produce more precise summary estimates of vaccine response.Keywords
This publication has 98 references indexed in Scilit:
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- On the relationship between mean antibody level, seroprotection and clinical protection from influenzaBiologicals, 2009
- Vaccines for preventing influenza in healthy children2008
- Response to influenza vaccine in people with non-protective HI antibody titersEuropean Journal of Epidemiology, 2006
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Mapping the Antigenic and Genetic Evolution of Influenza VirusScience, 2004
- Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?Virus Research, 2004
- A TritonX-100-split Virion Influenza Vaccine is Safe and Fulfills the Committee for Proprietary Medicinal Products (CPMP) Recommendations for the European Community for Immunogenicity, in Children, Adults and the ElderlyBiologicals, 2000
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972